Oxeia Biopharmaceuticals, Inc. — Form C/A (Regulation Crowdfunding)
Oxeia Biopharmaceuticals, Inc. of Boston, MA filed a Form C/A (Regulation Crowdfunding) with the SEC on 2026-01-15. Target raise $20K, up to $1.2M. Offered through StartEngine Primary, LLC.
Offering
- Filed: 2026-01-15
- Form: C/A
- Accession: 0001610315-26-000005
- Target amount: $20K
- Maximum amount: $1.2M
- Security type: Other
- Securities offered: 25,316
- Price: $0.7900
- Deadline: 2026-04-06
- Funding portal / intermediary: StartEngine Primary, LLC
- Intermediary file number: 008-70060
Issuer
- CIK: 0001610315
- Website: https://www.oxeiabiopharma.com/
- Legal status: Corporation
- Organized in: DE
- Incorporated: 2014-03-19
- Address: 361 Newbury Street, Boston, MA, 02115
- Employees: 2
Financials (as filed)
- Total assets (most recent): $233K
- Cash (most recent): $25K
- Net income (most recent): $-1.2M
- Net income (prior): $-1.9M
- Short-term debt: $8.5M
- Long-term debt: $3.9M
People (3)
| Name | Role | Location |
|---|
| Kartik Kiran Shah | Board Member | Boston, MA |
| Michael Steven Wyand | Chief Executive Officer, Principal Accounting Officer, Director | Boston, MA |
| Teofilo David Raad | Director | Boston, MA |
Reg CF filing history (6)
More